Physiomics Share Price | |
---|---|
Price | 1.50 |
Bid | 1.40 |
Ask | 1.60 |
Change | 0.00 (0.00%) |
Volume | 0 |
Open | 0.00 |
High | 0.00 |
Low | 0.00 |
Prev. Close | 1.50 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 135.47m |
Market Capitalisation | £2.03m |
Market Size | 30,000 |
52 Week High | 3.15 |
52 Week High Date | 10-May-2023 |
52 Week Low | 0.925 |
52 Week Low Date | 09-Aug-2023 |
# Trades | 0 |
---|---|
Vol. Sold | 0 |
Sold Value | £N/A |
Vol. Bought | 0 |
Bought Value | £N/A |
PE Ratio | -3.061224 |
Earnings | -0.49 |
Dividend | 0.00 |
Yield | 0.00% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
25-Apr-24 | 16:02:38 | 1.436 | 16,000 | Sell* | 1.40 | 1.60 | 229.76 | O Ordinary |
25-Apr-24 | 16:02:04 | 1.518 | 100,000 | Sell* | 1.50 | 1.60 | 1,518 | O Ordinary |
25-Apr-24 | 15:33:55 | 1.5165 | 198,450 | Sell* | 1.50 | 1.60 | 3,009 | O Ordinary |
25-Apr-24 | 15:15:37 | 1.515 | 145,551 | Sell* | 1.50 | 1.60 | 2,205 | O Ordinary |
25-Apr-24 | 15:13:48 | 1.558 | 63,929 | Buy* | 1.40 | 1.60 | 996.01 | O Ordinary |
25-Apr-24 | 15:12:20 | 1.52 | 131,316 | Buy* | 1.40 | 1.60 | 1,996 | O Ordinary |
25-Apr-24 | 15:11:51 | 1.52 | 131,316 | Buy* | 1.40 | 1.60 | 1,996 | O Ordinary |
25-Apr-24 | 15:10:42 | 1.479 | 67,343 | Buy* | 1.40 | 1.50 | 996.00 | O Ordinary |
25-Apr-24 | 13:03:56 | 1.499 | 8,000 | Buy* | 1.40 | 1.50 | 119.92 | O Ordinary |
25-Apr-24 | 13:03:30 | 1.403 | 6,000 | Sell* | 1.40 | 1.50 | 84.18 | O Ordinary |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
25-Jul-23 | 22-Jul-23 | Transfer To | James Simon Millen held the position of Executive Chairman at the time of this trade.James Simon Millen | 0.00 | 500,000 | 1,884,393 | |
18-Jul-23 | 14-Jul-23 | Transfer To | Christophe Chassagnole held the position of COO at the time of this trade.Christophe Chassagnole | 0.00 | 500,000 | 1,102,723 | |
29-Jun-21 | 28-Jun-21 | Transfer To | Christophe Chassagnole held the position of COO at the time of this trade.Christophe Chassagnole | 0.00 | 85,715 | 602,723 | |
21-May-21 | 21-May-21 | Transfer To | James Simon Millen held the position of CEO at the time of this trade.James Simon Millen | 0.00 | 242,287 | 1,384,393 | |
22-Mar-21 | 29-Jan-21 | Transfer To | James Simon Millen held the position of CEO at the time of this trade.James Simon Millen | 0.00 | 242,287 | 1,384,393 |
Physiomics is a leading oncology drug development consultancy using proprietary state of the artVirtual Tumour™ technology and other tools to predict and better understand the effects of cancer treatments. We work with partners developing cancer drugs to help them save time and money during pre-clinical and clinical development.